| Valuation |
6.6 |
auto |
P/E 83.4 |
| Liquidity |
3.6 |
auto |
Current ratio 0.67 |
| Growth |
7.0 |
auto |
Revenue growth 10.0% |
| Profitability |
6.4 |
auto |
Net margin 6.9% |
| Efficiency |
10.0 |
auto |
ROE 6225.0% |
| Leadership Tenure |
7.5 |
ai |
CEO Robert Michael took over July 2024 from longtime CEO Rick Gonzalez (who led 2013-2024); transition was orderly with Michael previously serving as President/COO, but tenure is still short. |
| Ownership Alignment |
4.0 |
auto |
Insider holding 0.12% |
| Strategic Vision |
8.6 |
ai |
Clear post-Humira pipeline strategy anchored on Skyrizi and Rinvoq (combined ~$27B+ run-rate, guided to $31B by 2027), plus neuroscience (Vraylar, Botox), oncology (Venclexta, Epkinos), and aesthetics; well-articulated path through the Humira LOE. |
| Focus / Clarity |
8.2 |
ai |
Tightly focused on immunology, oncology, neuroscience, and aesthetics under a coherent specialty pharma thesis; Allergan integration is now mature and the portfolio reads as four clear therapeutic franchises. |
| Diversification |
8.4 |
ai |
Revenue ~$56B spread across Skyrizi, Rinvoq, Botox (therapeutic + cosmetic), Vraylar, Venclexta, Imbruvica, and aesthetics; no single product post-Humira erosion exceeds ~25% of revenue, and global geographic spread is solid. |
| Maturity / Revenue |
9.3 |
ai |
Revenue $61.2B |
| Growth Potential |
8.1 |
ai |
Skyrizi/Rinvoq are the fastest-growing immunology drugs globally with multi-indication expansion (IBD, dermatology, rheumatology), plus oncology bispecifics (Epkinly), neuroscience (emraclidine setback notwithstanding), and Cerevel/ImmunoGen acquisitions extending the runway in a $200B+ specialty pharma TAM. |
| Volatility |
8.0 |
auto |
β 0.36 · D/E n/a |
| Market Standing |
9.1 |
auto |
Market cap $349.7B |
| Competitive Moat |
8.3 |
ai |
Patent-protected blockbusters Skyrizi (IL-23) and Rinvoq (JAK1) with composition-of-matter protection into mid-2030s, Botox brand/clinical moat in aesthetics and therapeutics, and strong specialty distribution; top-3 global pharma with ~14% R&D intensity. |